Drugs / Pazufloxacin
Pazufloxacin
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02980523 | Mar 2015 → Jun 2016 | bacterial conjunctivitis | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03696342 | Oct 2018 → Mar 2020 | bacterial conjunctivitis | Laboratorios Sophia S.A de C.V. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pazufloxacin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03696342 ↗ |
| Known as | Pazufloxacine | ChEMBL registry synonym — accepted as the source's own label CHEMBL240163 ↗ |
| Known as | Pazufloxacino | ChEMBL registry synonym — accepted as the source's own label CHEMBL240163 ↗ |
| Known as | PRO-157 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02980523 ↗ |
| Known as | T-3761 | ChEMBL registry synonym — accepted as the source's own label CHEMBL240163 ↗ |
| Modality | Small molecule | — CHEMBL240163 ↗ |
| Route | Other | “instill one drop in each eye of PRO-157 (pazufloxacin), every 12 hours per day (BID), for 7 days” NCT02980523 ↗ |